{"commentary":{"count":53,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":24,"podcast":22,"x_thread":7},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06533826\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"TRADE DXd","nct_id":"NCT06533826","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=trade-dxd-nct06533826. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"TRADE DXd","arms":[{"description":"Enrolled participants will complete:\n\n* Baseline visit with tumor biopsy, imaging, electrocardiogram and echocardiogram.\n* Tumor biopsy between Cycle 2 Day 1 and Day 8.\n* Imaging every 9 weeks.\n* Cycle 1 through Cycle 3:\n\n  --Day 1 of 21 day cycle: Predetermined dose of Trastuzumab deruxtecan 1x daily.\n* Cycle 4 through end of treatment:\n\n  * Day 1 of 21 day cycle: Predetermined dose of Trastuzumab deruxtecan 1x daily.\n  * Imaging on Day 1.\n* End of Treatment visit with imaging, tumor biopsy, echocardiogram\n* Follow up: imaging every 9 weeks.\n* Long-term Follow Up: visits every 6 months.","label":"Arm A (ADC1 T-DXd HR+)","type":"EXPERIMENTAL"},{"description":"Enrolled participants will complete:\n\n* Baseline visit with tumor biopsy, imaging, electrocardiogram and echocardiogram.\n* Tumor biopsy between Cycle 2 Day 1 and Day 8.\n* Imaging every 9 weeks.\n* Cycle 1 through end of treatment:\n\n  --Day 1 of 21 day cycle: Predetermined dose of Trastuzumab deruxtecan 1x daily.\n* Cycle 4 through end of treatment:\n\n  * Day 1 of 21 day cycle: Predetermined dose of Trastuzumab deruxtecan 1x daily.\n  * Imaging on Day 1.\n* End of Treatment visit with imaging, tumor biopsy, echocardiogram\n* Follow up: imaging every 9 weeks.\n* Long-term Follow Up: visits every 6 months.","label":"Arn B (ADC1 T-DXd HR-)","type":"EXPERIMENTAL"},{"description":"Enrolled participants will complete:\n\n* Baseline visit with tumor biopsy, imaging, electrocardiogram and eye exam.\n* Tumor biopsy between Cycle 2 Day 1 and Day 8.\n* Imaging every 9 weeks.\n* Cycle 1 through end of treatment:\n\n  --Day 1 of 21 day cycle: Predetermined dose of Datopotamab deruxtecan 1x daily.\n* Cycle 4 through end of treatment:\n\n  * Day 1 of 21 day cycle: Predetermined dose of Datopotamab deruxtecan 1x daily.\n  * Imaging on Day 1.\n* End of Treatment visit with imaging, tumor biopsy, eye exam.\n* Follow up: imaging every 9 weeks.\n* Long-term Follow Up: visits every 6 months.","label":"Arm C (ADC1 Dato-DXd HR+)","type":"EXPERIMENTAL"},{"description":"Enrolled participants will complete:\n\n* Baseline visit with tumor biopsy, imaging, electrocardiogram and eye exam.\n* Tumor biopsy between Cycle 2 Day 1 and Day 8.\n* Imaging every 9 weeks.\n* Cycle 1 through Cycle 3:\n\n  --Day 1 of 21 day cycle: Predetermined dose of Datopotamab deruxtecan 1x daily.\n* Cycle 4 through end of treatment:\n\n  * Day 1 of 21 day cycle: Predetermined dose of Datopotamab deruxtecan 1x daily.\n  * Imaging on Day 1.\n* End of Treatment visit with imaging, tumor biopsy, eye exam.\n* Follow up: imaging every 9 weeks.\n* Long-term Follow Up: visits every 6 months.","label":"Arm D (ADC1 Dato-DXd HR-)","type":"EXPERIMENTAL"},{"description":"Participants will complete:\n\n* Baseline visit with imaging, tumor biopsy, electrocardiogram, eye exam.\n* Imaging every 9 weeks.\n* Cycle 1 through Cycle 3:\n\n  --Day 1 of 21 day cycle: Predetermined dose of Datopotamab deruxtecan 1x daily.\n* Cycle 4 through end of treatment:\n\n  * Day 1 of 21 day cycle: Predetermined dose of Datopotamab deruxtecan 1x daily.\n  * Imaging on Day 1.\n* End of Treatment visit with imaging, tumor biopsy, eye exam.\n* Follow up: imaging every 9 weeks.\n* Long-term Follow Up: visits every 6 months.","label":"Arm E (ADC2 Dato-DXd HR+)","type":"EXPERIMENTAL"},{"description":"Participants will complete:\n\n* Baseline visit with imaging, tumor biopsy, electrocardiogram, eye exam.\n* Imaging every 9 weeks.\n* Cycle 1 through Cycle 3:\n\n  --Day 1 of 21 day cycle: Predetermined dose of Datopotamab deruxtecan 1x daily.\n* Cycle 1 through end of treatment:\n\n  * Day 1 of 21 day cycle: Predetermined dose of Datopotamab deruxtecan 1x daily.\n  * Imaging on Day 1.\n* End of Treatment visit with imaging, tumor biopsy, eye exam.\n* Follow up: imaging every 9 weeks.\n* Long-term Follow Up: visits every 6 months.","label":"Arm F (ADC2 Dato-DXd HR-)","type":"EXPERIMENTAL"},{"description":"Participants will complete:\n\n* Baseline visit with imaging, tumor biopsy, electrocardiogram, echocardiogram.\n* Imaging every 9 weeks.\n* Cycle 1 through Cycle 3:\n\n  --Day 1 of 21 day cycle: Predetermined dose of Trastuzumab deruxtecan 1x daily.\n* Cycle 1 through end of treatment:\n\n  * Day 1 of 21 day cycle: Predetermined dose of Trastuzumab deruxtecan 1x daily.\n  * Imaging on Day 1.\n* End of Treatment visit with imaging, tumor biopsy, echocardiogram\n* Follow up: imaging every 9 weeks.\n* Long-term Follow Up: visits every 6 months.","label":"Arm G (ADC2 T-DXd HR+)","type":"EXPERIMENTAL"},{"description":"Participants will complete:\n\n* Baseline visit with imaging, tumor biopsy, electrocardiogram, echocardiogram.\n* Imaging every 9 weeks.\n* Cycle 1 through Cycle 3:\n\n  --Day 1 of 21 day cycle: Predetermined dose of Trastuzumab deruxtecan 1x daily.\n* Cycle 1 through end of treatment:\n\n  * Day 1 of 21 day cycle: Predetermined dose of Trastuzumab deruxtecan 1x daily.\n  * Imaging on Day 1.\n* End of Treatment visit with imaging, tumor biopsy, echocardiogram\n* Follow up: imaging every 9 weeks.\n* Long-term Follow Up: visits every 6 months.","label":"Arm H (ADC2 T-DXd HR-)","type":"EXPERIMENTAL"}],"collaborators":["AstraZeneca","Translational Breast Cancer Research Consortium"],"completion_date":{"date":"2038-08-01","type":"ESTIMATED"},"conditions":["Breast Cancer","HER2-low Breast Cancer","Metastatic Breast Cancer","HER2-negative Breast Cancer"],"enrollment":{"count":357,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Trastuzumab Deruxtecan","type":"DRUG"},{"name":"Datopotamab Deruxtecan","type":"DRUG"}],"last_update":"2026-08-26","lead_sponsor":"Ana C Garrido-Castro, MD","official_title":"A Phase II Non-comparative Trial of Datopotamab Deruxtecan (Dato-DXd) or Trastuzumab Deruxtecan (T-DXd) in Patients With Metastatic HER2-negative (HER2-low or HER2-0) Breast Cancer After Progression on Prior Antibody Drug Conjugate Therapy","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2028-01-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Objective Response Rate in ADC1 (Group 1) Cohort","timeFrame":"The observation period related to this endpoint is up to 36 months."},{"measure":"Objective Response Rate in ADC2 (Group 2) Cohort","timeFrame":"The observation period related to this endpoint is up to 36 months."}],"references":[],"start_date":{"date":"2024-10-29","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd","url":"https://clinicaltrials.gov/study/NCT06533826"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/trade-dxd-nct06533826"}